Cost Effectiveness Analysis of an Ancillary Study of the REMOTEV Study

• Conditions: Venous Thromboembolic Disease

• Registration Number: NCT03887806
• Lead Sponsor: University Hospital, Strasbourg, France

Brief Summary

The implications of the medico-economic impact are essential in the choice of first-line therapists. The economic impact is an important criterion to recommend the privileged use of Direct Oral Anticoagulants (AOD) in first intention.

Detailed Description

Not available

Study Timeline

• Status Verified: 2019-03
• Study Start: 2019-03-20
• Study First Submitted: 2019-03-20
• Study First Submitted QC: 2019-03-21
• Last Update Submitted: 2019-03-21
• Study First Posted: 2019-03-25
• Last Update Posted: 2019-03-25
• Primary Completion: 2020-03-20
• Study Completion: 2020-03-20

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cost-effectiveness analysis between 2 therapeutic strategies, Direct Oral Anticoagulants (Rivaroxaban) versus standard anticoagulant (AVK)	The period from November 1st, 2013 to July 01, 2015 will be examined	Cost-effectiveness analysis between 2 therapeutic strategies: The costs related to each strategy are calculated taking into account the direct and indirect costs.

Trial Locations

Locations (1)

Service Des Maladies Vasculaires - Hta - Nhc; 🇫🇷 Strasbourg, France